JACC: Cardiovascular Interventions · 2019 · 33 citations · 27 references
MedicineSurgeryInterventional CardiologyVascular SurgeryVascular Surgery Of The HeadArterial InterventionsBalloon AngioplastyChronic Total Occlusion InterventionEndovascular SurgeryLower Extremity RevascularizationChronic Total Occlusion AngioplastyCulprit Lesion RevascularizationFemoral Artery AngioplastyFemoropopliteal DiseaseFemoropopliteal InterventionPeripheral AngioplastyPrimary PatencyTarget Lesion Revascularization
OBJECTIVES: The aim of this study was to evaluate the Tack Endovascular System (Intact Vascular, Wayne, Pennsylvania) for treating dissections following angioplasty in the superficial femoral artery and/or proximal popliteal artery. BACKGROUND: Dissection after angioplasty of femoropopliteal arteries with either a plain balloon or a drug-coated balloon (DCB) can negatively affect both short- and long-term outcomes. METHODS: TOBA (Tack Optimized Balloon Angioplasty) II is a prospective, single-arm, multicenter study enrolling 213 patients, all with dissection following angioplasty. Eligibility included Rutherford classification 2 to 4 with a de novo or nonstented restenotic lesion in the superficial femoral artery or proximal popliteal artery undergoing plain balloon or DCB angioplasty. Following dilation, lesions with <30% residual stenosis and presence of ≥1 dissection were enrolled. The 12-month efficacy endpoint was primary patency (freedom from duplex-derived binary restenosis and clinically driven target lesion revascularization. RESULTS: Patients' mean age was 68 ± 9 years, and 43.2% had diabetes. Twenty-three percent of lesions were chronic total occlusions, and ∼60% had moderate to severe calcium. The mean lesion length was 74.3 ± 40.6 mm. Severe dissection (grade ≥C) was present in 69.4%. By operator choice, 57.7% of patients underwent DCB angioplasty. Most (92.1%) dissections resolved completely, and only 1 bailout stent was required. There were no 30-day major adverse events. The 12-month efficacy endpoint was met, with Kaplan-Meier primary patency and freedom from clinically driven target lesion revascularization of 79.3% and 86.5%, respectively. At 12 months, there were no device fractures or clinically significant migrations, and significant improvements were noted in Rutherford category, ankle-brachial index, and quality of life. CONCLUSIONS: TOBA II demonstrated the safety and efficacy of the Tack Endovascular System for focal dissection repair following standard and DCB angioplasty.
27
EuroQol - a new facility for the measurement of health-related quality of life
Health Policy · 1990 · 15.8K citations
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Lars Norgren, William R. Hiatt, John Dormandy et al. · Journal of Vascular Surgery · 2007 · 8.2K citations · Full text
Medicine, Cardiology, Surgery +15